Hands On Diagnostics Study Finds A Groundbreaking Approach to Treating Neuropathy with the NeuFit NEUBIE Device

The multi-site clinical trial finds significant improvements in pain, sensation, and nerve signaling.

AUSTIN, Texas, Feb. 5, 2025 /PRNewswire/ -- NeuFit is revolutionizing neurological rehabilitation with its innovative approach that integrates advanced diagnostics and therapeutic technologies. At the center of NeuFit's success is the NEUBIE (Neuro-Bio-Electric Stimulator), a cutting-edge device that utilizes direct current (DC) electrical stimulation to promote accelerated recovery, enhance performance, and improve overall well-being. A recently published study in the Journal of Diabetes Research highlights NeuFit's unique approach in collaboration with Hands-On Diagnostics (HODS) to address neuropathy. The study shows striking results through a comparison of the NEUBIE device to traditional transcutaneous electrical nerve stimulation (TENS) devices for treating diabetic peripheral neuropathy. Treatment with the NEUBIE significantly improved pain reduction, motor function, sensory deficits, and nerve conduction, while TENS showed no significant improvements.

View PDF

"Neuropathy is incredibly common among the aging population, regardless of disease states. There is currently no known cure for neuropathy, and most treatments address acute symptoms with no lasting impact," says Dr. Ramona von Leden, VP of Research and Clinical Affairs for NeuFit. "NeuFit's specialized approach to rehab focuses on supporting the function of the nervous system, and we are seeing remarkable results on patients with neuropathy."

Unlike conventional methods that primarily focus on structural rehabilitation, the NEUBIE targets the nervous system, the body's control center for responses to injury or dysfunction. The use of DC over traditional alternating current (AC) in the NEUBIE device sets NeuFit apart from other electrical stimulation therapies. This promotes healing, reduces pain, and improves sensorimotor function more rapidly than AC, which can hinder effective therapy and reinforce inefficient movement patterns.

Neuropathy, characterized by nerve damage that results in pain, weakness, and numbness, presents significant treatment challenges. NeuFit and HODS are making groundbreaking strides in this area by combining advanced diagnostics with innovative therapy. HODS specializes in electromyography (EMG) and nerve conduction studies, providing detailed insights into nerve function. By integrating these diagnostic tools with NeuFit's therapeutic approach, patients receive comprehensive evaluations and tailored treatment plans that can be adjusted in real-time for optimal results.

"The findings from this study show that we can make tangible improvements to nerve function and related subjective measures in patients suffering from neuropathy," continues Dr. von Leden. "NeuFit's innovative approach, combined with HODS' diagnostic expertise, is redefining neurological rehabilitation. By focusing on the nervous system and leveraging advanced technology, NeuFit offers a promising future for patients with challenging conditions like neuropathy."

Link to article: https://onlinelibrary.wiley.com/doi/10.1155/jdr/9970124

Citation: Kostopoulos, Dimitrios, Rizopoulos, Konstantine, McGilvrey, Joe, Hauskey, Jennifer, Courcier, Jeff, Connor-Israel, Kay, Koster, Harry, von Leden, Ramona, An Open-Label Comparative Study of the Impact of Two Types of Electrical Stimulation (Direct Current Neuromuscular Electrical Stimulation and Transcutaneous Electrical Stimulation) on Physical Therapy Treatment of Diabetic Peripheral Neuropathy, Journal of Diabetes Research, 2025, 9970124, 10 pages, 2025. https://doi.org/10.1155/jdr/9970124

Media Contact:
Dr. Ramona von Leden, PhD
Vice President of Research and Clinical Affairs
[email protected]
https://www.neu.fit/contact/

SOURCE NeuFit